Page 37 - Lexaria Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hill Street Reports FY 2021 Third Quarter Results and Provides Update on Operations Hill Street Beverage Company Inc. reported its third quarter results for the period ended March 31, 2021. A complete set of financial statements and Management’s Discussion & Analysis has been filed at All dollar figures are quoted in Canadian dollars. The third quarter of FY21 saw continued momentum for the Company as it demonstrated progress toward its ambition to pioneer the unique space where craft consumer … Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) report...

Hill Street Beverage Company Inc.: Hill Street Reports FY 2021 Third Quarter Results and Provides Update on Operations Hill Street" or the " Company") reported its third quarter results for the period ended March 31, 2021. A complete set of financial statements and Management's Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars. The third quarter of FY21 saw continued momentum for the Company as it demonstrated progress toward its ambition to pioneer the unique space where craft consumer products meet bioscience, combining deep CPG experti...

PCG Digital: Lexaria DehydraTECH 2.0 Outperforms MCT in 2021 R&D Study New York, New York--(Newsfile Corp. - May 25, 2021) - PCG Digital -- The positive results keep rolling in for Lexaria (LEXX). They recently released R&D study results for three new DehydraTECH TM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard. Though new to NASDAQ, Lexaria Bioscience Corp. has been producing positive test results with their patented DehydraTECH TM bio-absorption technology since 2016. The process has been used in foo...

Lexaria Bioscience Corp.: Lexaria's Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH 2.0" cannabidiol ("CBD") formulations in its second 2021 applied research and development study program, HYPER-A21-2. "One of ...

Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever ACCESSWIRE New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new 'DehydraTECH ™ 2.0' cannabidiol ('CBD') formulations in its second 2021 applied res...